Ilene Ceil Weitz, MD

Professor of Clinical Medicine (Part-Time)

Image of Ilene Ceil Weitz, MD
Is this your profile? Click to edit


Dr. Ilene C. Weitz is an Associate Professor of Clinical Medicine at the Keck School of Medicine at the University of Southern California (USC). Her practice sites include, LAC+USC Medical Center, Keck Hospital of USC and USC Norris Cancer Hospital. Dr. Weitz is board certified in Internal Medicine and Hematology.

Dr. Weitz earned her medical degree at Medical College of Pennsylvania in Philadelphia, followed by an internship and residency in internal medicine at Cedars-Sinai Medical Center. She conducted a fellowship in hematology/oncology at Scripps Clinic and Research Foundation in La Jolla, California.

Dr. Weitz is a member of the Academy-Simmons College Honor Society, Alpha Omega Alpha, American Medical Womens Association, Los Angeles County Medical Women’s Association, Alumni Associations of Medical College of Pennsylvania and Cedars-Sinai Medical Center, American Society of Hematology, and American Society of Clinical Oncology. She received the Morris Press Humanism Award in 1987 and the “Golden Apple” Outstanding Physician Educator Award in 1990 from Cedars-Sinai Medical Center, as well as the Outstanding Voluntary Faculty Award in the Division of Hematology from USC School of Medicine. Dr Weitz has delivered nationwide lectures and has been published in numerous journals, including American Journal of Clinical Pathology, Hepatology, and Journal of Clinical Oncology, American Journal of Hematology.. She has also contributed eight book chapters or reviews.

Dr. Weitz’ research and clinical interests include hematologic disorders such as anemias, thrombocytopenia and white blood cell disorders, paroxysmal nocgturnal hemoglobinurua (PNH), immune mediated anemias and thrombocytopenia, thrombosis and hemostasis.


  • Division of Hematology, Keck School of Medicine: Outstanding Voluntary Faculty, 1996
  • Cedars-Sinai Medical Center: Golden Apple Outstanding Physician Educator Award, 1990
  • Cedars-Sinai Medical Center: Morris Press Humanism Award, 1987
  • Alpha Omega Alpha: Elected Member, 1976
  • Simmons College: Academy Honor Society, 1971


  • Correction to: Sutimlimab improves quality of life in patients with cold agglutinin disease: results of patientreported outcomes from the CARDINAL study Ann Hematol. 2024 May; 103(5):1803. . View in PubMed
  • Sutimlimab provides clinically meaningful improvements in patient-reported outcomes in patients with cold agglutinin disease: Results from the randomised, placebo-controlled, Phase 3 CADENZA study Eur J Haematol. 2023 Mar; 110(3):280-288. . View in PubMed
  • Complement in immune thrombocytopenia (ITP): The role of complement in refractory ITP Br J Haematol. 2023 10; 203(1):96-100. . View in PubMed
  • Am J Hematol. 2023 08; 98(8):1246-1253. . View in PubMed
  • Biomarkers and laboratory assessments for monitoring the treatment of patients with paroxysmal nocturnal hemoglobinuria: Differences between terminal and proximal complement inhibition Blood Rev. 2023 05; 59:101041. . View in PubMed
  • Long-term sutimlimab improves quality of life for patients with cold agglutinin disease: CARDINAL 2-year follow-up Blood Adv. 2023 10 10; 7(19):5890-5897. . View in PubMed
  • Pegcetacoplan: A New Opportunity for Complement Inhibition in PNH J Blood Med. 2023; 14:239-245. . View in PubMed
  • Sutimlimab improves quality of life in patients with cold agglutinin disease: results of patient-reported outcomes from the CARDINAL study Ann Hematol. 2022 Oct; 101(10):2169-2177. . View in PubMed
  • Pegcetacoplan versus eculizumab in patients with paroxysmal nocturnal haemoglobinuria (PEGASUS): 48-week follow-up of a randomised, open-label, phase 3, active-comparator, controlled trial Lancet Haematol. 2022 Sep; 9(9):e648-e659. . View in PubMed
  • Sutimlimab in patients with cold agglutinin disease: results of the randomized placebo-controlled phase 3 CADENZA trial Blood. 2022 09 01; 140(9):980-991. . View in PubMed
  • Complement C1s inhibition with sutimlimab results in durable response in cold agglutinin disease: CARDINAL study 1-year interim follow-up results Haematologica. 2022 07 01; 107(7):1698-1702. . View in PubMed
  • Effectiveness and safety of tacrolimus with or without eltrombopag, as a part of immunosuppressive treatment of aplastic anemia in adults: a retrospective case series Ann Hematol. 2021 Apr; 100(4):933-939. . View in PubMed
  • Acute ST-Segment Elevation Myocardial Infarction as Initial Presentation of Atypical Hemolytic-Uremic Syndrome JACC Case Rep. 2021 Apr; 3(4):561-565. . View in PubMed
  • Response to: Eculizumab package insert recommendations for meningococcal vaccinations: call for clarity and a targeted approach for use of the drug in neuromyelitis optica spectrum disorder CNS Spectr. 2021 06; 26(3):195-196. . View in PubMed
  • Characterization of breakthrough hemolysis events observed in the phase 3 randomized studies of ravulizumab versus eculizumab in adults with paroxysmal nocturnal hemoglobinuria Haematologica. 2021 01 01; 106(1):230-237. . View in PubMed
  • Complement Factor D as a Strategic Target for Regulating the Alternative Complement Pathway Front Immunol. 2021; 12:712572. . View in PubMed
  • Pegcetacoplan versus Eculizumab in Paroxysmal Nocturnal Hemoglobinuria N Engl J Med. 2021 03 18; 384(11):1028-1037. . View in PubMed
  • Cost burden of breakthrough hemolysis in patients with paroxysmal nocturnal hemoglobinuria receiving ravulizumab versus eculizumab Hematology. 2020 Dec; 25(1):327-334. . View in PubMed
  • Acute dilated cardiomyopathy in the setting of catastrophic antiphospholipid syndrome and thrombotic microangiopathy: A case series and review EJHaem. 2020 Jul; 1(1):44-50. . View in PubMed
  • C3 inhibition with pegcetacoplan in subjects with paroxysmal nocturnal hemoglobinuria treated with eculizumab Am J Hematol. 2020 11; 95(11):1334-1343. . View in PubMed
  • Multidrug Therapy for Refractory Immune Thrombocytopenia in Pregnancy Obstet Gynecol. 2020 03; 135(3):723-727. . View in PubMed
  • A Retrospective Study of the Combination of Rituximab, Cyclophosphamide and Dexamethasone for the Treatment of Relapsed/Refractory Warm Antibody Autoimmune Hemolytic Anemia Acta Haematol. 2020; 143(3):244-249. . View in PubMed
  • Thrombotic Microangiopathy in Cancer Semin Thromb Hemost. 2019 Jun; 45(4):348-353. . View in PubMed
  • Ethnic and racial difference in Helicobacter pylori infection in patients with immune thrombocytopenia treated at a major urban medical center Platelets. 2019; 30(3):413-417. . View in PubMed
  • Effective treatment of chemotherapy induced atypical Haemolytic Uraemic Syndrome: a case series of 7 treated patients Br J Haematol. 2018 10; 183(1):136-139. . View in PubMed
  • Thrombotic microangiopathy in cancer Thromb Res. 2018 04; 164 Suppl 1:S103-S105. . View in PubMed
  • Complement-mediated thrombotic microangiopathy associated with lupus nephritis Blood Adv. 2018 08 28; 2(16):2090-2094. . View in PubMed
  • Autoimmune Hemolytic Anemia Med Clin North Am. 2017 Mar; 101(2):351-359. . View in PubMed
  • OC-14 – Baseline D-dimer levels are predictive of recurrent venous thromboembolism (VTE) at 6 months in cancer patients with VTE treated with tinzaparin Thromb Res. 2016 Apr; 140 Suppl 1:S174. . View in PubMed
  • Life-threatening delayed hyperhemolytic transfusion reaction in a patient with sickle cell disease: effective treatment with eculizumab followed by rituximab Transfusion. 2015 Oct; 55(10):2398-403. . View in PubMed
  • Eculizumab in Pregnant Patients with Paroxysmal Nocturnal Hemoglobinuria N Engl J Med. 2015 Sep 10; 373(11):1032-9. . View in PubMed
  • Adding ascorbic acid to arsenic trioxide produces limited benefit in patients with acute myeloid leukemia excluding acute promyelocytic leukemia Ann Hematol. 2014 Nov; 93(11):1839-43. . View in PubMed
  • Complement the hemostatic system: an intimate relationship Thromb Res. 2014 May; 133 Suppl 2:S117-21. . View in PubMed
  • A prospective multicenter study of paroxysmal nocturnal hemoglobinuria cells in patients with bone marrow failure Cytometry B Clin Cytom. 2014 May; 86(3):175-82. . View in PubMed
  • Atypical hemolytic uremic syndrome: the role of complement pathway gene mutation analysis Clin Adv Hematol Oncol. 2014 Apr; 12(4):266-8. . View in PubMed
  • Atypical haemolytic-uraemic syndrome due to heterozygous mutations of CFH/CFHR1-3 and complement factor H 479 Blood Transfus. 2014 Jan; 12(1):111-3. . View in PubMed
  • A Prospective Multicenter Study of Paroxysmal Nocturnal Hemoglobinuria Cells in Patients with Bone Marrow Failure Cytometry B Clin Cytom. 2013 Oct 11. . View in PubMed
  • Cross-sectional validation study of patient-reported outcomes in patients with paroxysmal nocturnal haemoglobinuria Intern Med J. 2013 Mar; 43(3):298-307. . View in PubMed
  • Clinical roundtable monograph: Paroxysmal nocturnal hemoglobinuria: a case-based discussion Clin Adv Hematol Oncol. 2012 Nov; 10(11 Suppl 21):1-16. . View in PubMed
  • Eculizumab therapy results in rapid and sustained decreases in markers of thrombin generation and inflammation in patients with PNH independent of its effects on hemolysis and microparticle formation Thromb Res. 2012 Sep; 130(3):361-8. . View in PubMed
  • A novel approach to the evaluation of bleeding-related episodes in patients with chronic immune thrombocytopenia Curr Med Res Opin. 2012 May; 28(5):789-96. . View in PubMed
  • Thrombosis in patients with paroxysmal nocturnal hemoglobinuria Semin Thromb Hemost. 2011 Apr; 37(3):315-21. . View in PubMed
  • Thrombosis in Paroxysmal Nocturnal Hemoglobinuria – insights into the role of complement in thrombosis Thromb Res. 2010 Apr; 125 Suppl 2:S106-7. . View in PubMed
  • Immune thrombocytopenia in patients with connective tissue disorders and the antiphospholipid antibody syndrome Hematol Oncol Clin North Am. 2009 Dec; 23(6):1239-49. . View in PubMed
  • The role of oral anticoagulants in tumor biology Semin Thromb Hemost. 2007 Oct; 33(7):695-8. . View in PubMed
  • Successful rituximab therapy of acquired factor VIII inhibitor in a patient with rheumatoid arthritis J Clin Rheumatol. 2007 Apr; 13(2):89-91. . View in PubMed
  • Treatment of immune thrombocytopenia associated with interferon therapy of hepatitis C with the anti-CD20 monoclonal antibody, rituximab Am J Hematol. 2005 Feb; 78(2):138-41. . View in PubMed
  • Thromboembolic complications of cancer: epidemiology, pathogenesis, diagnosis, and treatment Am J Hematol. 2003 Jan; 72(1):43-52. . View in PubMed
  • Invest New Drugs. 2002 Nov; 20(4):369-76. . View in PubMed
  • Chemotherapy-induced activation of hemostasis: effect of a low molecular weight heparin (dalteparin sodium) on plasma markers of hemostatic activation Thromb Haemost. 2002 Aug; 88(2):213-20. . View in PubMed
  • Enhancement of fluorouracil uptake in human colorectal and gastric cancers by interferon or by high-dose methotrexate: An in vivo human study using noninvasive (19)F-magnetic resonance spectroscopy J Clin Oncol. 2000 Jan; 18(2):255-61. . View in PubMed
  • Tamoxifen-associated venous thrombosis and activated protein C resistance due to factor V Leiden Cancer. 1997 May 15; 79(10):2024-7. . View in PubMed
  • Des-gamma-carboxy (abnormal) prothrombin and hepatocellular carcinoma: a critical review Hepatology. 1993 Oct; 18(4):990-7. . View in PubMed
  • Excessive fibrinolysis in amyloidosis associated with elevated plasma single-chain urokinase Am J Clin Pathol. 1992 Nov; 98(5):534-41. . View in PubMed